Advertisement

Topics

Hairmax Lasercomb For The Treatment Of Androgenetic Alopecia In Females

2014-07-23 21:11:13 | BioPortfolio

Summary

HairMax 12 2009-F-02 is a double blind study to evaluate the treatment of androgenetic alopecia.

Description

Treatment is applied as directed per device three nonconcurring days a week for 16 & 26 weeks. This is a randomized, double-blind, sham control clinical study evaluating changes in terminal hair-count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hairs). Approximately 15 female subjects will be randomized at our clinical sites. Key inclusion criteria are female subjects who: have been diagnosed with Androgenetic Alopecia, are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Ludwig I-4, II-1, II-2, or frontal hair loss, and have active hair loss at time of enrollment.

Study Design

Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Androgenetic Alopecia

Intervention

Hairmax Lasercomb

Location

The Cleveland Clinic
Cleveland
Ohio
United States
44195

Status

Recruiting

Source

The Cleveland Clinic

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:11:13-0400

Clinical Trials [91 Associated Clinical Trials listed on BioPortfolio]

Treatment of Androgenetic Alopecia in Males

The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 7 Beam model in promoting hair growth in men diagnosed with androgenetic alopecia when treatment is appl...

Treatment of Androgenic Alopecia in Males

The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 9 & 12 Beam models in promoting hair growth in men diagnosed with androgenetic alopecia when treatment i...

Treatment of Androgenetic Alopecia in Females, 9 Beam

The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 9 beam model in promoting hair growth in females diagnosed with androgenetic alopecia when treatment is ...

Treatment of Androgenetic Alopecia in Females, 12 Beam

The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 12 beam model for androgenetic alopecia in females when treatment is applied as directed.

HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis

The purpose of this study is to test whether the stimulation of vascularization and cellular metabolism on the scalp by use of the HairMax LaserComb will produce improvement in the conditi...

PubMed Articles [106 Associated PubMed Articles listed on BioPortfolio]

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version.

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss ...

Serum androgens and PSA levels in androgenetic alopecia - is there a difference between frontal and vertex baldness?

Androgenetic alopecia (AGA) seems to be a marker of increased risk of prostate cancer (PCa).

Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia, and fibrosing alopecia in a pattern distribution?

Frequent coexistence of frontal fibrosing alopecia (FFA) and androgenetic alopecia (AGA) has been reported in the literature, but little attention has been given to the pathogenetic mechanisms underly...

An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia.

Androgenetic alopecia is a condition with a high prevalence worldwide and affects both males and females. Currently, only 2 approved treatments exist: finasteride (males only) and minoxidil 2 or 5% so...

A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women.

Currently, only topical minoxidil (MNX) and oral finasteride (FNS) are approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of androgenetic alop...

Medical and Biotech [MESH] Definitions

Absence of hair from areas where it is normally present.

A microscopically inflammatory, usually reversible, patchy hair loss occurring in sharply defined areas and usually involving the beard or scalp. (Dorland, 27th ed)

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Benign childhood alopecia that improves spontaneously with aging. It is characterized by anagen hairs (misshapen hair bulbs and absent inner and outer root sheaths), thin, and sparse hairs that pulls out easily.

A syndrome characterized by bilateral granulomatous UVEITIS with IRITIS and secondary GLAUCOMA, premature ALOPECIA, symmetrical VITILIGO, poliosis circumscripta (a strand of depigmented hair), HEARING DISORDERS, and meningeal signs (neck stiffness and headache). Examination of the cerebrospinal fluid reveals a pattern consistent with MENINGITIS, ASEPTIC. (Adams et al., Principles of Neurology, 6th ed, p748; Surv Ophthalmol 1995 Jan;39(4):265-292)

More From BioPortfolio on "Hairmax Lasercomb For The Treatment Of Androgenetic Alopecia In Females"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...


Searches Linking to this Trial